LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

LLY

799.18

-2.76%↓

UNH

480.67

-0.1%↓

JNJ

162.95

+0.07%↑

NVO

75.8

+1.46%↑

ABBV

211.23

-0.3%↓

Search

Arrowhead Pharmaceuticals Inc

Cerrado

Sector Salud

15.01 -5

Resumen

Variación precio

24h

Actual

Mínimo

14.8

Máximo

15.83

Métricas clave

By Trading Economics

Ingresos

-1.9M

-175M

Ventas

2.5M

2.5M

BPA

-1.39

Margen de beneficio

-7,008.72

Empleados

609

EBITDA

4.9M

-148M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+157.45 upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.1B

Apertura anterior

20.01

Cierre anterior

15.01

Noticias sobre sentimiento de mercado

By Acuity

45%

55%

165 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Arrowhead Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 sept 2024, 10:38 UTC

Principales Movimientos del Mercado

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Comparación entre iguales

Cambio de precio

Arrowhead Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

157.45% repunte

Estimación a 12 meses

Media 40.6 USD  157.45%

Máximo 80 USD

Mínimo 21 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arrowhead Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 18.09Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

165 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.